186 related articles for article (PubMed ID: 9704709)
1. Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer.
Weaver A; Chang J; Wrigley E; de Wynter E; Woll PJ; Lind M; Jenkins B; Gill C; Wilkinson PM; Pettengell R; Radford JA; Collins CD; Dexter TM; Testa NG; Crowther D
J Clin Oncol; 1998 Aug; 16(8):2601-12. PubMed ID: 9704709
[TBL] [Abstract][Full Text] [Related]
2. Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor.
Basser RL; To LB; Begley CG; Maher D; Juttner C; Cebon J; Mansfield R; Olver I; Duggan G; Szer J; Collins J; Schwartz B; Marty J; Menchaca D; Sheridan WP; Fox RM; Green MD
J Clin Oncol; 1998 May; 16(5):1899-908. PubMed ID: 9586908
[TBL] [Abstract][Full Text] [Related]
3. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial.
Facon T; Harousseau JL; Maloisel F; Attal M; Odriozola J; Alegre A; Schroyens W; Hulin C; Schots R; Marin P; Guilhot F; Granena A; De Waele M; Pigneux A; Méresse V; Clark P; Reiffers J
Blood; 1999 Aug; 94(4):1218-25. PubMed ID: 10438709
[TBL] [Abstract][Full Text] [Related]
4. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
5. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients.
Glaspy JA; Shpall EJ; LeMaistre CF; Briddell RA; Menchaca DM; Turner SA; Lill M; Chap L; Jones R; Wiers MD; Sheridan WP; McNiece IK
Blood; 1997 Oct; 90(8):2939-51. PubMed ID: 9376574
[TBL] [Abstract][Full Text] [Related]
6. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
[TBL] [Abstract][Full Text] [Related]
7. Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor.
Weaver A; Ryder D; Crowther D; Dexter TM; Testa NG
Blood; 1996 Nov; 88(9):3323-8. PubMed ID: 8896396
[TBL] [Abstract][Full Text] [Related]
8. Stem cell factor leads to reduced blood processing during apheresis or the use of whole blood aliquots to support dose-intensive chemotherapy.
Weaver A; Testa NG
Bone Marrow Transplant; 1998 Jul; 22(1):33-8. PubMed ID: 9678793
[TBL] [Abstract][Full Text] [Related]
9. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection.
Engelhardt M; Bertz H; Afting M; Waller CF; Finke J
J Clin Oncol; 1999 Jul; 17(7):2160-72. PubMed ID: 10561272
[TBL] [Abstract][Full Text] [Related]
10. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I/II trial.
Moskowitz CH; Stiff P; Gordon MS; McNiece I; Ho AD; Costa JJ; Broun ER; Bayer RA; Wyres M; Hill J; Jelaca-Maxwell K; Nichols CR; Brown SL; Nimer SD; Gabrilove J
Blood; 1997 May; 89(9):3136-47. PubMed ID: 9129016
[TBL] [Abstract][Full Text] [Related]
11. Application of whole blood and peripheral blood progenitor cells (PBPC) and new strategies for rescue after intensive cyclic chemotherapy in high-risk breast cancer.
Filip S; Bláha M; Odrázka K; Mericka P; Vávrová J
J Hematother Stem Cell Res; 2000 Feb; 9(1):31-8. PubMed ID: 10738969
[TBL] [Abstract][Full Text] [Related]
12. A study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide.
Weaver A; Wrigley E; Watson A; Chang J; Collins CD; Jenkins B; Gill C; Pettengell R; Dexter TM; Testa NG; Crowther D
Br J Cancer; 1996 Dec; 74(11):1821-7. PubMed ID: 8956800
[TBL] [Abstract][Full Text] [Related]
13. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization.
Kopf B; De Giorgi U; Vertogen B; Monti G; Molinari A; Turci D; Dazzi C; Leoni M; Tienghi A; Cariello A; Argnani M; Frassineti L; Scarpi E; Rosti G; Marangolo M
Bone Marrow Transplant; 2006 Sep; 38(6):407-12. PubMed ID: 16951690
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.
Somlo G; Sniecinski I; ter Veer A; Longmate J; Knutson G; Vuk-Pavlovic S; Bhatia R; Chow W; Leong L; Morgan R; Margolin K; Raschko J; Shibata S; Tetef M; Yen Y; Forman S; Jones D; Ashby M; Fyfe G; Hellmann S; Doroshow JH
Blood; 1999 May; 93(9):2798-806. PubMed ID: 10216073
[TBL] [Abstract][Full Text] [Related]
15. Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim.
To LB; Bashford J; Durrant S; MacMillan J; Schwarer AP; Prince HM; Gibson J; Lewis I; Swart B; Marty J; Rawling T; Ashman L; Charles S; Cohen B
Bone Marrow Transplant; 2003 Mar; 31(5):371-8. PubMed ID: 12634728
[TBL] [Abstract][Full Text] [Related]
16. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
17. Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis.
Möhle R; Pförsich M; Fruehauf S; Witt B; Krämer A; Haas R
Bone Marrow Transplant; 1994 Nov; 14(5):827-32. PubMed ID: 7534163
[TBL] [Abstract][Full Text] [Related]
18. Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer previously treated with chemotherapy.
Prósper F; Solá C; Hornedo J; Arbona C; Menéndez P; Orfao A; Lluch A; Cortés-Funes H; López JJ; García-Conde J
Leukemia; 2003 Feb; 17(2):437-41. PubMed ID: 12592344
[TBL] [Abstract][Full Text] [Related]
19. Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients.
Kröger N; Zeller W; Fehse N; Hassan HT; Krüger W; Gutensohn K; Lölliger C; Zander AR
Br J Haematol; 1998 Sep; 102(4):1101-6. PubMed ID: 9734664
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
